Enrollment Begins in KNOCOUT PE Study of Ekos Therapy Protocols for Pulmonary Embolism
December 14, 2017—BTG International announced the commencement of the KNOCOUT PE study, which will measure how hospitals and patients are benefitting from a new standard of care in the treatment of pulmonary embolism (PE) utilizing the company's Ekos therapy with faster and safer protocols, which were proven effective in the OPTALYSE PE study.
The OPTALYSE PE study, which was presented in May at the American Thoracic Society International Conference in Washington, DC, found that PE can effectively be treated with Ekos therapy over a much shorter period of time and at safer thrombolytic doses that are far below the previous standard.
According to the company, the KNOCOUT PE study is expected to include up to 100 centers internationally. Cases will include those from before and after the release of the OPTALYSE PE study.
In BTG's announcement, KNOCOUT PE Principal Investigator Keith Sterling, MD, commented, “The results of the OPTALYSE PE trial suggest that a new standard for PE treatment might be adopted. The question is: how are institutions adjusting to these new low-dose, shorter-duration treatments, and what are they finding? KNOCOUT PE accelerates the sharing and learning process and continues to build on the body of clinical evidence, including the ULTIMA and SEATTLE II studies.”